TransCelerate’s Clinical Quality Management System: Issue Management

被引:0
作者
Susan Callery-D’Amico
Leslie M. Sam
Timothy H. Grey
Daniel J. Greenwood
机构
[1] AbbVie Inc,R&D Quality Assurance
[2] Eli Lilly and Company Lilly Corporate Center,Global Quality Systems
[3] Boehringer-Ingelheim Pharmaceutical Inc,Quality Medicine
来源
Therapeutic Innovation & Regulatory Science | 2016年 / 50卷
关键词
TransCelerate; quality management system; clinical development; issue management; risk management;
D O I
暂无
中图分类号
学科分类号
摘要
Issue management is one of the elements of the TransCelerate clinical quality management (QMS) conceptual framework. Effective issue management benefits clinical development organizations by allowing them to focus efforts on those issues that materially impact patient safety, rights, and well-being; data integrity and/or scientific rigor; compliance with regulatory requirements; or trust in the clinical research enterprise, which have been defined as “Issues that Matter.” Issue management begins with a triage of issues to identify those issues that materially impact as defined above, which are then handled by an end-to-end corrective and preventive action (CAPA) process. An added benefit of a well-defined issue management framework is the capability for trending and analytics designed to provide data and insights into risk management and knowledge management efforts.
引用
收藏
页码:530 / 535
页数:5
相关论文
empty
未找到相关数据